The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Goncharova Z.A.

Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Rostov-na-Donu

Sizyakina L.P.

The Research Institute of Clinical Immunology of Rostov State Medical University, Rostov-on-Don, Russia

Belovolova R.A.

GBOU VPO «Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet» Minzdrava Rossii, Rostov-na-Donu

Megeryan V.A.

Rostov State Medical University, Rostov-on-Don, Russia

Comorbid autoimmune pathology in patients treated with disease modifying drugs

Authors:

Goncharova Z.A., Sizyakina L.P., Belovolova R.A., Megeryan V.A.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2): 53‑60

DOI: 10.17116/jnevro201611610253-60

Read: 3111 times

Download PDF (RU)
Contact the author
Table of contents

COMORBID AUTOIMMUNE PATHOLOGY IN PATIENTS TREATED WITH DISEASE MODIFYING DRUGS
COMORBID AUTOIMMUNE PATHOLOGY IN PATIENTS TREATED WITH DISEASE MODIFYING DRUGS

To cite this article:

Goncharova ZA, Sizyakina LP, Belovolova RA, Megeryan VA. Comorbid autoimmune pathology in patients treated with disease modifying drugs. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(10‑2):53‑60. (In Russ.)
https://doi.org/10.17116/jnevro201611610253-60

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Cognitive impairment in patients with multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):67-73
Mole­cular mechanisms of acute disseminated ence­phalomyelitis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):7-11
The role of mono­cytes in the immu­nopathogenesis of multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):23-27
Resu­lts of a 5-year project for the early diagnosis of multiple scle­rosis in first-line blood rela­tives (RADIRS program). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):28-33
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Quantitative analysis of cere­brospinal fluid flow in multiple scle­rosis patients. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):45-50
A clinical case of X-linked adre­noleukodystrophy. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4):102-107
Arti­ficial inte­lligence capa­bilities in multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(5):14-21
Application of T-cells with chimeric anti­gen rece­ptor in the treatment of refractory autoimmune diseases. Russian Journal of Preventive Medi­cine. 2025;(7):106-110
Abstract:

Because of intensive growth of the prevalence of multiple sclerosis (MS) and other autoimmune diseases (AID) during the last years, the comorbidity of MS and AID is not a rarity. In this literature review, the development of comorbid AID in patients with MS is considered to be the probable complication of disease modifying therapy with drugs of different groups. The authors present the own data on the prevalence of comorbid autoimmune pathology in patients with MS treated with disease modifying drugs.

Keywords:

multiple sclerosis
comorbid pathology
autoimmune diseases
disease modifying drugs

Authors:

Goncharova Z.A.

Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet, Rostov-na-Donu

Sizyakina L.P.

The Research Institute of Clinical Immunology of Rostov State Medical University, Rostov-on-Don, Russia

Belovolova R.A.

GBOU VPO «Rostovskiĭ gosudarstvennyĭ meditsinskiĭ universitet» Minzdrava Rossii, Rostov-na-Donu

Megeryan V.A.

Rostov State Medical University, Rostov-on-Don, Russia

Close metadata

References:

  1. Yoshizaki A, Miyagaki T. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. Nature. 2012;491(7423):264-268. doi: 10.1038/nature11501
  2. Gusev EI, Zavalishin IA, Boyko AN i dr. Epidemiological features of multiple sclerosis in Russia. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (suppl «Multiple sclerosis»). 2002;102:3-5. (In Russ.).
  3. Grytten N, Torkildsen O, Myhr K.-M. Time trends in the incidence and prevalence of multiple sclerosis in Norway during eight decades. Acta Neurol Scand. 2015;132(suppl. 199):29-36. doi: 10.1111/ane.12428
  4. Dong YH, Fu D-G. Autoimmune thyroid disease: mechanism, genetics and current knowledge. European Review for Medical and Pharmacological Sciences. 2014;18:3611-3618.
  5. Deretzi G et al. Familial prevalence of autoimmune disorders in multiple sclerosis in Northern Greece. Multiple Sclerosis. 2010;16(9):1091-1101. doi: 10.1177/1352458510375708
  6. Goncharova ZA, Sizyakina LP, Megeryan VA. Comorbid autoimmune diseases in patients with multiple sclerosis (literature review). Jurnal mezhdunarodnoy mediciny. 2015;145-150. (In Russ.).
  7. Kasumagic-Halilovic E, Ovcina-Kurtovic N. Vitiligo and autoimmunity. Med Arch. 2013;67(2):91-93.
  8. Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology. 2013;227(4):311-315. doi: 10.1159/000354607
  9. Nejad SB, Qadim HH. Frequency of autoimmune diseases in those suffering from vitiligo in comparison with normal population. Pak J Biol Sci. 2013;16(12):570-574.
  10. Ramagopalan SV et al. Multiple sclerosis and co-morbid autoimmune disease: the final nail in the coffin? Multiple Sclerosis Journal. 2012;118(10):1370-1371.
  11. Ruth AM, Reider N. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Systematic Review. Multiple sclerosis journal. 2015;21(3):282-293. doi: 10.1177/1352458514564490
  12. Deretzi G, Kountouras J. Polyautoimmunity in a Greek cohort of multiple sclerosis. Acta Neurol Scand. 2015;131(4):225-230. doi: 10.1111/ane.12308
  13. Sirota M, Marc A et al. Autoimmune Disease Classification by Inverse Association with SNP Alleles. PLoS Genet. 2009;5(12). doi: 10.1371/journal.pgen.1000792
  14. Roshanisefat H, Bahmanyar S. Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis. Mult Scler. 2012;18(10):1430-1436.
  15. Hemminki K, Li X. Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions. Neurogenetics. 2009;10(1):5-11. doi: 10.1007/s10048-008-0156-y
  16. Petrova LV. Influence of the therapy with glatiramere acetatis (copaxone) on the sctructure and function of thyroid gland in patients with multiple sclerosis. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 2010;112:12:41-45. (In Russ.).
  17. Subei А, Ontaneda D. Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple Sclerosis. CNS Drugs. 2015;29(9):759-771. doi: 10.1007/s40263-015-0277-4
  18. Bagir LV, Batysheva TT. Thyroid gland pathology and multiple sclerosis: probable influence on efficiency and tolerability of the treatment. Zhurnal nevropatologii i psikhiatrii im. S.S. Korsakova. 2009;109:10-15. (In Russ.).
  19. Kiseliova EV, Spirin NN, Aleksandrov YuK, Leinova EV. Disseminated sclersis in thyroid glad pathology: the peculiarities of its couse and clinical semiology. Clinicheskaya medicina. 2014;19:18-21. (In Russ.).
  20. Kiseleva EV, Spirin NN. Neurological and immunological characteristics of multiple sclerosis with thyroid pathology. Medical sciences. 2015;1-5:962-966. (In Russ.).
  21. Awakawa T, Hirohashi S. A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C. Nihon Shokakibyo Gakkai Zasshi. 2003;100(6):680-684.
  22. Murata K, Shiraki K. Mono-arthritis following intensified interferon beta therapy for chronic hepatitis C. Hepatogastroenterology. 2002;49(47):1418-1419.
  23. D'Amico E, Paroli M. Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection. Digestive diseases and sciences. 1995;40(10):2113-2116.
  24. Watanabe U, Hashimoto E. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. The American Journal of gastroenterology. 1994;89(3):399-403.
  25. Tran HA, Reeves GE. The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-alpha Therapy for Chronic Hepatitis C. International journal of endocrinology. 2009. doi: 10.1155/2009/241786
  26. Tran HA, Jones TL. Thyroid disease in chronic hepatitis C infection treated with combination interferon-α and ribavirin: management strategies and future perspective. Endocr Pract. 2013;19(2):292-300. doi: 10.4158/EP12195.RA
  27. [No authors listed]] Interferon-ax and transfer factor in the treatment of multiple sclerosis: a double-blind, placebo-controlled trial. Journal of Neurology, Neurosurgery, and Psychiatry. 1989;52:566-574.
  28. Durelli L, Bongioanni MR. Interferon alpha treatment of relapsing-remitting multiple sclerosis: long-term study of the correlations between clinical and magnetic resonance imaging results and effects on the immune function. Mult Scler. 1995;1(suppl 1):32-37.
  29. Jansen M, Reinhard JF. Interferon response heterogeneity: activation of a pro-inflammatory response by interferon alpha and beta. A possible basis for diverse responses to interferon beta in MS. J Leukoc Biol. 1999;65(4):439-443.
  30. Nonchev BI. Cases of interferon-alpha and interferon-beta-induced thyroiditis. Folia Med (Plovdiv). 2010;52(3):5-12.
  31. Krysiak R, Boldys A. Autoimmune polyglandular syndrome type 2 induced by treatment with interferon alpha. Am J Med Sci. 2011;341(6):504-507. doi: 10.1097/MAJ.0b013e31820ff7af
  32. Masuda Saeko, Mori Masahiro. Autoimmune polyendocrine syndrome type 3 in a multiple sclerosis patient. Clinical & Experimental Neuroimmunology. 2015;6(3):299-303. doi: 10.1016/j.humimm.2013.06.020
  33. Bahri DM, Khiari H. Systemic lupus erythematosus induced by interferon [beta]1 therapy in a patient with multiple sclerosis. Fundamental & Clinical Pharmacology. 2012;26(2):210-211. doi: 10.1111/j.1472-8206.2011.00929.x
  34. Heesen C, Gbadamosi J. Autoimmune hyperthyroidism in multiple sclerosis under treatment with glatiramer acetate--a case report. Eur J Neurol. 2001;8(2):199.
  35. Rotondi M, Stufano F. Interferon-β but not Glatiramer acetate stimulates CXCL10 secretion in primary cultures of thyrocytes: a clue for understanding the different risks of thyroid dysfunctions in patients with multiple sclerosis treated with either of the two drugs. J Neuroimmunol. 2011;234(1-2):161-164. doi: 10.1016/j.jneuroim.2011.01.013
  36. Fernández Fernández N, Joao Matias D. Hepatitis induced by glatiramer acetate. Gastroenterol Hepatol. 2015;38(4):280-281. doi: 10.1136/bcr.09.2008.0913
  37. La Gioia S, Bacis G. Glatiramer acetate-induced hepatitis in a young female patient with multiple sclerosis. Mult Scler Relat Disord. 2014;3(6):732-734. doi: 10.1016/j.msard.2014.08.001
  38. Flaire A, Carra-Dalliere C. Glatiramer acetate-induced hepatitis in a patient with multiple sclerosis. Acta Neurol Belg. 2015.
  39. Frese A, Bethke F. Development of myasthenia gravis in a patient with multiple sclerosis during treatment with glatiramer acetate. J Neurol. 2000;247(9):713.
  40. Ettinger О.А. Chronic hepatitis С: thyroid status condition during the treatment with interferon–alfa: [abstract of dissertation]. М. 2000. (In Russ.). (1&S21REF=5&S21FMT=fullwebr&C21COM=S&S21CNR=10&S21P01=0&S21P02=1&S21P03=A=&S21STR=ЭТТИНГЕР,%20Ольга%20Александровна ccылка активна на 20.04.16.
  41. Tran HA, Reeves GE. The Spectrum of Autoimmune Thyroid Disease in the Short to Medium Term Following Interferon-α Therapy for Chronic Hepatitis C. Int J Endocrinol. 2009;ID 241786 68. Vial T.
  42. Ridgway EC, Tomer Y, McLachlan SM. Update in thyroidology. J Clin Endocrinol Met. 2007;92(10):3755-3761.
  43. Lloyd AR, Jagger E, Post JJ et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cel Biol. 2007;85:24-32.
  44. Fernandez Soto L, Gonzales A, Escobar Jimenez F et al. Increased risk of autoimmune thyroid disease in hepatitis C vs hepatitis B before, during, and after discontinuing interferon therapy. Arch Intern Med. 1998;158:1445-1448.
  45. Hsieh MC, Yu ML, Chuang WL et al. Virologic factors related to interferon-α-induced thyroid dysfunction in patients with chronic hepatitis C. Eur J Endocrin. 2000;142:431-437.
  46. Gensicke Henrik, Leppert David. Monoclonal Antibodies and Recombinant Immunoglobulins for the Treatment of Multiple Sclerosis. CNS Drugs. 2012;26(1):11-37. doi: 10.2165/11596920-000000000-00000
  47. Sturve O, Gold R. Alfa4-integrin antagonism with natalizumab. J Neurol. 2008;255(suppl 6):18-24, 58-65. doi: 10.1007/s00415-008-6011-0
  48. Sturve O, Gold R. Alfa4-integrin antagonism with natalizumab. J Neurol. 2008;255(suppl 6):18-24, 58-65. doi: 10.1007/s00415-008-6011-0
  49. Armuzzi A, Felice C. Natalizumab in Crohn’s disease: past and future areasof applicability. Annals of Gastroenterology. 2013;26:189-190.
  50. Lianjie Lin, Xiang Liu. Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease. A Systematic Review and Meta-Analysis. Medicine (Baltimore). 2015;94(10):556. doi: 10.1097/MD.0000000000000556
  51. Borie D, Kremer JM. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2015;45(2):163-166. doi: 10.1016/j.semarthrit.2015.06.003
  52. Oddo S, Laroni A. A case of thyroiditis during natalizumab therapy for multiple sclerosis. J Endocrinol Invest. 2011;34(5):408-409.
  53. Carcelén-Gadea M, Ferrer-Garcia JC. Transient autoimmune hyperthyroidism following the withdrawal of Natalizumab in patients with multiple sclerosis. Neurol Sci. 2013;34(12):2259-2261. doi: 10.1007/s10072-013-1497-3
  54. Hozumi Y, Kobayashi E. Immunotherapy for experimental rat autoimmune thyroiditis using a novel immunosuppressant, FTY720. Life Sci. 1999;65(17):1739-1745.
  55. Morohoshi K, Osone M. The sphingosine 1-phosphate receptor modulator FTY720 prevents iodide-induced autoimmune thyroiditis in non-obese diabetic mice. Autoimmunity. 2011;44(6):490-495. doi: 10.3109/08916934.2011.558145
  56. Kwiatkowski A, Gallois J, Bilbault N, Calais G, Mackowiak A, Hautecoeur P. Herpes encephalitis during natalizumab treatment in multiple sclerosis. Mult Scler. 2012;18:6:909-911. doi: 10.1177/1352458511428082
  57. Vorobyeva AA, Simaniv TO. Experience of Using Natalizumab (Tysabri) at the Research Center of Neurology. Effektivnaya Farmakoterapiya. 2014;58:4-11. (In Russ.).
  58. Bence G, Maria P. Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood. 2012;1:119:9:2176-2177. doi: 10.1182/blood-2011-10-388892
  59. Cao Y, Zhao D. Effects of immunosuppressants on immune response to vaccine in inflammatory bowel disease. Chin Med J (Engl). 2015;128(6):835-838. doi: 10.4103/0366-6999.152683
  60. McCarthy Claire L. Tuohy Orla MB. Immune competence after alemtuzumab treatment of multiple sclerosis. Neurology. 2013;81(10):872-876. doi: 10.1212/WNL.0b013e3182a35215
  61. Cossburn M, Pace AA. Autoimmune disease after alemtuzumab treatment for multiple sclerosis in a multicenter cohort. Neurology. 2011;77(6):573-579. doi: 10.1212/WNL.0b013e318228bec5
  62. Daniels Gilbert H, Vladic А. Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis. Journal of Clinical Endocrinology & Metabolism. 2014;99(1):80-89. doi: 10.1210/jc.2013-2201
  63. Kristen M Williams, MD, Danielle Dietzen, RN. Autoimmune Thyroid Disease Following Alemtuzumab Therapy and Hematopoietic Cell Transplantation in Pediatric Patients with Sickle Cell Disease. Pediatr Blood Cancer. 2014;61(12):2307-2309. doi: 10.1002/pbc.25102
  64. Kirk AD, Hale DA. Autoimmune Thyroid Disease After Renal Transplantation Using Depletional Induction with Alemtuzumab. American Journal of Transplantation. 2006;6:1084-1085.
  65. Malmeström C, Andersson BA, Lycke J. First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS. J Neurol. 2014;261(10):2016-2018. doi: 10.1007/s00415-014-7448-y
  66. Ibitoye R, Wilkins A. Thyroid papillary carcinoma after alemtuzumab therapy for MS. J Neurol. 2014;261(9):1828-1829. doi: 10.1007/s00415-014-7453-1
  67. Costelloe L, Jones J, Coles A. Secondary autoimmune diseases following alemtuzumab therapy for multiple sclerosis. Expert Rev Neurother. 2012;12(3):335-341. doi: 10.1586/ern.12.5
  68. Loechelt BJ, Boulware D. Epstein-Barr and other herpesvirus infections in patients with early onset type 1 diabetes treated with daclizumab and mycophenolatemofetil. Clin Infect Dis. 2013;56(2):248-254. doi: 10.1093/cid/cis848
  69. Doskozhaeva ST. Immune reconstitution inflammatory syndrome (IRIS). Vestnik of KSMA КГМА im. I.К. Аkhunbaeva. 2013;1:67-70. (In Russ.).
  70. Tan IL, McArthur JC. Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology. 2011;77(11):1061-1067. doi: 10.1212/WNL.0b013e31822e55e7
  71. Sinha A, Abinun M. Graves' immune reconstitution inflammatory syndrome in childhood. Thyroid. 2013;23(8):1010-1014. doi: 10.1089/thy.2012.0618
  72. Daum S, Moos V. Immune reconstitution inflammatory syndrome (IRIS) of the small bowel in an immunocompromised patient suffering from systemic lupus erythematosus and non-tuberculous mycobacteriosis. Z Rheumatol. 2008;67(4):277-278, 280-283. doi: 10.1007/s00393-008-0298-1
  73. Weetman A. Immune reconstitution syndrome and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009;23(6):693-702. doi: 10.1016/j.beem.2009.07.003
  74. Joze´lio Freire de Carvalho. Pearls in autoimmunity. Autoimmun Highlights. 2011;2:1-4. doi: 10.1007/s13317-011-0016-x
  75. Timothy B. Niewold. Type I interferon in human autoimmunity. Frontiers in immunology. EDITORIAL published. 2014. doi: 10.3389/fimmu.2014.00306
  76. Tozzoli R, Sorrentino MC, Bizzaro N. Detecting multiple autoantibodies to diagnose autoimmune co-morbidity (multiple autoimmune syndromes and overlap syndromes): a challenge for the autoimmunologist. Immunol Res. 2013;56(2-3):425-431. doi: 10.1007/s12026-013-8418-7
  77. Blewett MM. Lipid autoreactivity in multiple sclerosis. Med Hypotheses. 2010;74(3):433-442. doi: 10.1016/j.mehy.2009.10.003
  78. Masuda H. Serum antinuclear antibody may be associated with less severe disease activity in neuromyelitis optica. Eur J Neurol. 2016;23(2):276-281. doi: 10.1111/ene.12714
  79. Li H, Dai Y. Anti-thyroid antibodies and cerebrospinal fluid findings in neuromyelitis optica spectrum disorders. J Neuroimmunol. 2015;281:38-43. doi: 10.1016/j.jneuroim.2015.02.014
  80. Youming Long. Serum Thyroid-Stimulating Hormone and Anti-Thyroglobulin Antibody Are Independently Associated with Lesions in Spinal Cord in Central Nervous System Demyelinating Diseases. Plos one. 2014;9:8:100672.
  81. Wright C, Sibani S, Trudgian D, et al. Detection of Multiple Autoantibodies in Patients with Ankylosing Spondylitis Using Nucleic Acid Programmable Protein Arrays. Molecular & Cellular Proteomics: MCP. 2012;11(2):M9.00384. doi: 10.1074/mcp.M9.00384
  82. Julie M Robertson, Benjamin F Bruner. Multiple Autoantibodies Display Association with Lymphopenia, Proteinuria, and Cellular Casts in a Large, Ethnically Diverse SLE Patient Cohort. Hindawi Publishing Corporation. Autoimmune Diseases. 2012;Article ID 819634:11. doi: 10.1155/2012/819634
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.